Breakthrough in HIV Prevention: Lenacapavir Shows 100% Efficacy

A recent study published in The New England Journal of Medicine reveals that the HIV-preventive drug Lenacapavir shows 100 percent efficacy with no safety concerns in women. Conducted by Gilead Sciences, Inc., the phase-3 trial involving participants from South Africa and Uganda highlighted zero HIV infections in the Lenacapavir group.

A groundbreaking study published in The New England Journal of Medicine reported that Lenacapavir, an HIV-preventive drug, has shown 100 percent efficacy with no safety concerns in women. The study was conducted by US biopharmaceutical company Gilead Sciences, Inc.

Lenacapavir is an injectable drug administered twice a year developed as a pre-exposure prophylaxis (PrEP) to prevent HIV infection. The phase-3 trial involved teenage girls and young women in South Africa and Uganda, showing zero HIV infections in participants receiving Lenacapavir.

The study divided 5,338 HIV-negative participants into three groups, with one group receiving Lenacapavir injections every 26 weeks. Notably, the Lenacapavir group reported no HIV infections, whereas other groups reported multiple infections. These results offer a promising future for HIV prevention, especially in cisgender women.

(With inputs from agencies.)